Lapaquistat is an investigational drug.
There have been 16 clinical trials for Lapaquistat.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2005.
The most common disease conditions in clinical trials are Hypercholesterolemia, Dyslipidemias, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda and [disabled in preview].